Canadian Oncology Nursing Journal最新文献

Myeloproliferative neoplasms (MPNs) are a group of rare clonal disorders of hematopoietic progenitor cells associated with disease-related symptoms, thrombotic events, and risk of transformation to acute myeloid leukemia (Tefferi, 2021). The relative rarity and complexity of care led to the establishment of the MPN program at the Princess Margaret (PM) Cancer Centre. The MPN program utilizes a shared-care model wherein partnering with local hematologists (shared-care partners) ensures that patients have access to an MPN specialist while continuing to receive care close to home (Cheung et al., 2021). The clinical nurse specialist (CNS) role was implemented in late 2016 to support not only the shared-care model, but also to triage new patient referrals, and support consultation and follow-up. Although the CNS roles have been part of the healthcare system since the 1940s, the role and its impact remain unclear at times to the inter-disciplinary team. This paper will describe the process and results from evaluating the CNS role's impact in the MPN program using a multimethod approach. This is part one of two papers; herein the quantitative findings are presented, and part two will discuss the qualitative findings.

Cancer survivorship has gained increased awareness as a key aspect of cancer care over the past 40 years (Campbell et al., 2019; Halpern et al., 2016; National Research Council et al., 2006; Fitch et al., 2019; Marzorati et al., 2017, Romkey-Sinasac et al., 2021). Individuals living with and beyond gynecologic malignancies face unique cancer-related physical and psychosocial care needs that extend well beyond active treatment (Beesley et al., 2019). Underserved populations experience additional challenges due to intersecting disparities in social determinants of health deeply rooted structural and systemic barriers to healthcare (Canadian Cancer Statistics Advisory Committee, 2023; Helpman et al., 2022). A growing number of individuals will require survivorship care, as cancer incidence and survival rates increase in Canada (Brenner et al., 2024), and novel treatment approaches for gynecological cancers continue to progress (Harris, 2019). Oncology nurses play a pivotal role in providing ongoing assessment, comprehensive care coordination, and advocacy in cancer survivorship care for this population (Campbell et al., 2019; Cook et al., 2017; Horrill, 2022). This article provides an overview of current trends, unique needs, and implications for nursing practice in the care of all individuals living with and beyond endometrial, ovarian, and cervical cancers.

This study examines the Canadian radiation oncology nursing workforce through a Pan-Canadian Radiation Oncology Health Human Resources survey conducted by the Canadian Association of Nurses in Oncology/Association canadienne des infirmières (CANO/ACIO) partnered with the Canadian Association of Radiation Oncologists (CARO), the Canadian Organization of Medical Physicists (COMP), and the Canadian Association of Medical Radiation Technologists (CAMRT). The survey aimed to gather data on workforce capacity, workload, and scopes of practice, providing critical insights for predictive workforce modelling and policy development. The survey revealed significant variability in nursing full-time equivalents across radiation oncology centres, with large centres averaging more nursing staff per linear accelerator than small ones. The study also highlighted challenges in recruitment and retention, influenced by high workloads, prescriptive work schedules, and the need for specialized education. Despite these challenges, the shift toward team-based care models presents an opportunity to optimize nursing roles within radiation oncology, emphasizing the importance of specialized education and workforce planning. The findings underscore the necessity for a standardized approach to workforce modelling, considering patient acuity and other factors to ensure balanced resource allocation and improve care quality in radiation oncology settings.

Background: Synthesizing unique barriers to cancer-related care among rural and remote populations would be useful to inform future research and health service priorities. To fill this gap, the overall goal of this review is to synthesize the cancer literature about those living in rural and remote locations in Canada.

Methods: Using JBI scoping review methods, we extracted the following: definition of rural or remote; phase of cancer care continuum (screening, diagnosis, treatment/care, post-treatment, outcomes); province( s) and/or territory(ies) of the sample; and cancer diagnosis(es).

Results: Within the 45 studies, definitions of rural and remote varied widely. The treatment/care phase was most often reflected (n = 18) followed by screening (n = 12). All provinces were represented and data from the Yukon Territory was lacking. Breast and colorectal cancer diagnoses were most common (n = 20 and n = 18, respectively) and most studies (n = 31) used quantitative designs.

Conclusion: Review results illuminate the state of cancer-related research of rural and remote populations across Canada and highlight implications for further examination.

Myeloproliferative neoplasms (MPN) are a group of rare clonal disorders of hematopoietic progenitor cells associated with disease- related symptoms, thrombotic events, and risk of transformation to acute myeloid leukemia (Tefferi, 2021). Their relative rarity and complexity of care led to the establishment of the MPN program at the Princess Margaret (PM) Cancer Centre, Toronto, Canada. The MPN program utilizes a shared-care model wherein partnering with local hematologists (shared-care partners) ensures that patients have access to a MPN specialist while continuing to receive care close to home. The clinical nurse specialist (CNS) role was implemented in late 2016 to support not only the shared-care model, but also to triage new patient referrals, and support consultation and follow-up. Although the CNS role has been part of the healthcare system since the 1940s, the role and its impact remain unclear at times to the inter-disciplinary team. This paper describes the process and results in evaluating the CNS role's impact in the MPN program through using a multi-method approach. In this Part II of a series, the focus is on discussing the team and patient care experience with having a CNS as part of the care team.

Dr. Charissa Cordon has two decades of experience in healthcare, as a nurse, educator, and leader. She was recently appointed to the role of Associate Vice President for Practice and Academics at William Osler Health System. She has held other senior leadership roles such as Director of Professional Practice and Clinical Resource Team, Chief of Nursing Practice, and Chief of Interprofessional Practice in Oncology. With a wealth of experience as a transformational change leader in nursing and professional practice, she has led many initiatives at the local, provincial, and national levels. In her Keynote Address at the 2023 CANO/ACIO Conference, Charissa shared her personal reflections on her life experiences that shaped her values and principles as a leader, and provided examples of how she draws on her inner strength to lead during difficult and challenging times and shine a bright light to those around her. Today, as we continue with our post-pandemic recovery efforts, nurses and nurse leaders must continue to work together to support our young nurses who are new to the profession. We also need to continue to lift each other up, support each other, support our new leaders, and shine a bright light to those around us. Our strength as nurses and leaders, during a time of crisis comes from within us, individually from each of us, and together, as a collective whole.

Over the past several decades, there has been excellent progress in cervical cancer prevention and early detection. However, there are still many Canadian woman who will be diagnosed with cervical cancer and will require active treatment. Advancements in personalizing treatment options based on specific staging and fertility-sparing preferences have helped decrease morbidities for some while ensuring well-needed aggressive treatment for others. Surgical procedures, for example, offer a variety of options with curative intent, particularly for those with earlier stage disease. Once the cancer has spread beyond the cervix to locally advanced stages 2 and 3, the combination of chemotherapy and radiation tends to be the mainstay treatment option. Finally, as cancer becomes more advanced into later stages 3 and 4 disease, utilizing traditional chemotherapy with the addition of novel drugs, such as monoclonal antibodies and immune check point inhibitors, offers hope where it was once lacking. This article focuses on these varying treatment options and identifies how nurses are in the prime position to help patients improve overall understanding, tolerance, and continuity of their treatment plan.